Neurosense Therapeutics Stock Alpha and Beta Analysis
| NRSN Stock | USD 1.16 0.01 0.85% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Neurosense Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Neurosense Therapeutics over a specified time horizon. Remember, high Neurosense Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Neurosense Therapeutics' market risk premium analysis include:
Beta (1.65) | Alpha (0.02) | Risk 5.66 | Sharpe Ratio 0.0218 | Expected Return 0.12 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Neurosense |
Neurosense Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Neurosense Therapeutics market risk premium is the additional return an investor will receive from holding Neurosense Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Neurosense Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Neurosense Therapeutics' performance over market.| α | -0.02 | β | -1.65 |
Neurosense Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Neurosense Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Neurosense Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Neurosense Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Neurosense Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Neurosense Therapeutics shares will generate the highest return on investment. By understating and applying Neurosense Therapeutics stock market price indicators, traders can identify Neurosense Therapeutics position entry and exit signals to maximize returns.
Neurosense Therapeutics Return and Market Media
The median price of Neurosense Therapeutics for the period between Mon, Nov 18, 2024 and Sun, Feb 16, 2025 is 1.13 with a coefficient of variation of 11.13. The daily time series for the period is distributed with a sample standard deviation of 0.12, arithmetic mean of 1.12, and mean deviation of 0.1. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALSMND | 11/21/2024 |
2 | NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC | 12/11/2024 |
3 | NeuroSense Provides Business Update and Third Quarter 2024 Financial Results | 12/18/2024 |
4 | NeuroSense Regains Compliance with Nasdaqs Minimum Equity Requirement | 01/06/2025 |
About Neurosense Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Neurosense or other stocks. Alpha measures the amount that position in Neurosense Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 (projected) | Current Ratio | 0.84 | 0.97 | 0.92 | Net Debt To EBITDA | 0.23 | 0.27 | 0.26 |
Neurosense Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Neurosense Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neurosense Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Neurosense Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Neurosense Therapeutics. Please utilize our Beneish M Score to check the likelihood of Neurosense Therapeutics' management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Neurosense Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Neurosense Therapeutics Backtesting, Neurosense Therapeutics Valuation, Neurosense Therapeutics Correlation, Neurosense Therapeutics Hype Analysis, Neurosense Therapeutics Volatility, Neurosense Therapeutics History and analyze Neurosense Therapeutics Performance. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Neurosense Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.